Medical/Pharmaceuticals

SoniVie announces enrollment completion in the REDUCED-1 pilot study with TIVUS™ Ultra-Sound Renal Denervation

SoniVie announces enrollment completion in the REDUCED-1 pilot study TEL AVIV, Israel, Feb. 1, 2024 /PRNewswire/ -- SoniVie , an Israeli company developing a novel, proprietary Therapeutic Intra-Vascular Ultrasound (TIVUSTM) System to treat a variety of hypertensive diso...

2024-02-01 01:52 1736

Anbogen Secures 12.5 Million in Series A Funding, Advancing Precision Oncology Drug Development

TAIPEI, Jan. 31, 2024 /PRNewswire/ -- Anbogen Therapeutics, a clinical-stage biotechnology company specializing in groundbreaking cancer drug development, today announced the successful completion of its Series A funding round. The lead investor is China Development Industrial Bank (CDIB), with s...

2024-02-01 00:00 1653

Crystal Pharmatech's CDMO Business Unit - Crystal Formulations Services Successfully Passed EU QP Audit

SUZHOU, China, Jan. 31, 2024 /PRNewswire/ -- Recently, Crystal Formulations Services (CFS), the CDMO Business Unit of Crystal Pharmatech has achieved a significant milestone by successfully passing the on-site audit conducted by the European Qualified Person (QP), evaluating its GMP quality syste...

2024-01-31 21:00 1182

WuXi Biologics Successfully Completes First 1,6000L Manufacturing Run in Ireland

-  First manufacturing run successful for MFG7 facility at the Ireland site -  Largest manufacturing scale to date achieved by combining four 4,000-liter single-use bioreactors DUNDALK, Ireland, Jan. 31, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Researc...

2024-01-31 17:31 2486

IGIN: the first innovative device for automatic glove fitting, is now launching a pre-sale

DUBAI, UAE, Jan. 31, 2024 /PRNewswire/ -- Approximately 99,000 Americans die each year in hospitals due to infections acquired there, according to the Centres for Disease Control and Prevention (CDC). 3.5 million Europeans a year contract an infection while in hospital. IGIN Global

2024-01-31 17:13 1633

21ST.BIO OPENS A MORE SUSTAINABLE AVENUE FOR INDUSTRIAL SCALE DAIRY PROTEIN PRODUCTION

* Global bioproduction leader 21st.BIO today announced it is now granting access to its precision fermentation technology platform to food and ingredient manufacturers, enabling sustainable production of dairy proteins at competitive cost.            * Access to 21st.BIO's technology represen...

2024-01-31 16:47 1192

WuXi XDC Enters into Partnership with Multitude Therapeutics and HySlink Therapeutics, Novel Linker-Payload Technology Enabling Clients to Accelerate ADC Discovery and Development

SHANGHAI, Jan. 30, 2024 /PRNewswire/ -- WuXi XDC (2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on ADC and the other types of bioconjugate market; and Multitude Therapeutics, a clinical stage biotechnology company renowned for ADC platfor...

2024-01-31 10:43 2930

Synbio Tech's Innovative Probiotic Approach Revitalizes Gut and Vaginal Microbiota in Pregnant Women with Candidiasis

KAOHSIUNG, Jan. 31, 2024 /PRNewswire/ -- Innovative research and proprietary technologies have placed Synbio Tech, Inc. (1295:TT) at the forefront of the probiotics field. The company's advancements not only enhance probiotic production efficiency but also significantly benefit intestinal health,...

2024-01-31 09:00 2298

GMP cell CDMO I Peace, Inc. obtains accreditation as ISO 17025: 2017 compliant

Starts undertaking quality evaluation and characterization of iPSCs in accordance with ISO standards PALO ALTO, Calif. , Jan. 30, 2024 /PRNewswire/ -- Leading GMP cell CDMO I Peace, Inc. (https://www.ipeace.com ), specializing in induced pluripotent stem cells (iPSCs) an...

2024-01-31 05:46 1767

Universe Pharmaceuticals INC Reports Fiscal Year 2023 Financial Results

JI'AN, China, Jan. 30, 2024 /PRNewswire/ -- Universe Pharmaceuticals INC ("Universe Pharmaceuticals" or the "Company") (Nasdaq: UPC), a pharmaceutical producer and distributor inChina, today announced its financial results for the fiscal year endedSeptember 30, 2023. Mr. Gang Lai, Chairman and C...

2024-01-31 05:30 3069

Medtec China's 20th Anniversary brings together 1000+ Exhibitors and Facilitates Business Innovation in Shanghai in September

SHANGHAI, Jan. 31, 2024 /PRNewswire/ -- With the new favorable policy of encouraging the innovative development of advanced medical devices from the Guidance Catalogue for Industrial Structure Adjustment (2024), which announced by the National Development and Reform Commission , it indicates that...

2024-01-31 00:00 1810

The Biotech Accelerator Unicorn Program: A Unique Collaboration between CKGSB and the UC San Diego Rady School of Management

SAN DIEGO, Jan. 30, 2024 /PRNewswire/ -- Cheung Kong Graduate School of Business (CKGSB) andUniversity of California San Diego (UC San Diego) Rady School of Management are proud to announce the launch of the Biotech Accelerator Unicorn Program, a pioneering joint program specifically designed to...

2024-01-30 22:25 2033

Endogenex Receives IDE Approval to Initiate Pivotal Clinical Study

A Prospective, Randomized, Multicenter Study Assessing the Safety and Efficacy of the ReCET™ System in Adult Patients with Type 2 Diabetes MINNEAPOLIS, Jan. 31, 2024 /PRNewswire/ -- Endogenex, Inc., a clinical stage medical device company dedicated to improving outcomes in patients with Type 2 D...

2024-01-30 22:00 1678

XtalPi Unveils Ailux: A New Chapter in AI-Powered Biologics Discovery

CAMBRIDGE, Mass., Jan. 30, 2024 /PRNewswire/ -- XtalPi Inc. (XtalPi), a globally leading innovative R&D platform company that harnesses the power of artificial intelligence (AI), quantum physics-based computation, and robotic automation to advance the discovery and evolution of groundbreaking th...

2024-01-30 21:00 1603

Singleron launches the AccuraSCOPE® Single Cell Transcriptome

COLOGNE, Germany, Jan. 30, 2024 /PRNewswire/ -- Singleron Biotechnologies, a leader in single cell multi-omic solutions for precision medicine,announced two new commercial product launches : AccuraSCOPE® Single Cell Transcriptome and Genome Library Kit and the AccuraSCOPE® Single Cell Full-Length...

2024-01-30 18:05 1368

Results of the Phase III INSPIRE Study on Qilu Pharmaceutical's Iruplinalkib Published in the Journal of Thoracic Oncology

JINAN, China, Jan. 30, 2024 /PRNewswire/ -- The interim analysis results from the phase III INSPIRE study of iruplinalkib developed by Qilu Pharmaceutical, which focuses on the first-line treatment of locally advanced or metastatic anaplastic lymphoma kinase (ALK)-positive non-small cell lung can...

2024-01-30 16:45 1547

DP Technology Announces Nomination of Development Candidate, a Potential Best-in-Class Kv1.3 Inhibitor for Immunological Diseases Including IBD and AD

* The nomination of novel Kv1.3 inhibitor DPT0218 for the treatment of various immunological diseases including IBD and AD. • DPT0218 is a gut-restricted, highly potent and selective Kv1.3 inhibitor with excellent in vivo efficacy and safety profile in preclinical studies.  * This project fur...

2024-01-30 16:32 1851

MGI Unveils Comprehensive Expansion of Automation Product Lines for Life Science and Healthcare Research

The company will offer new and improved solutions for sample pre-treatment, sample preparation and integrated testing, leveraging its innovative technologies and expertise in genetic sequencing and multi-omics. SHENZHEN, China, Jan. 30, 2024 /PRNewswire/ -- MGI Tech Co., Ltd. (referred to as MGI...

2024-01-30 15:55 1924

Vesicure Therapeutics made notable advancements using exosomes to target KRAS mutation

SUZHOU, China, Jan. 29, 2024 /PRNewswire/ -- SiRNA technology offers distinct advantages over conventional approaches, with the potential to target virtually any gene. This technology has emerged as a great strategy for treating a range of diseases, including cancer, viral infections, and genetic...

2024-01-29 21:30 1485

Oricell Announces FDA Clearance of IND Application for OriCAR-017, a novel GPRC5D Targeted CAR-T Cell Therapy Utilizing the Company's Proprietary Platform, for the Treatment of Relapsed/Refractory Multiple Myeloma.

SHANGHAI and ROSELAND, N.J., Jan. 29, 2024 /PRNewswire/ -- Oricell Therapeutics (Oricell), a clinical-stage biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for OriCAR-017 for patients with...

2024-01-29 21:08 1767
1 ... 9899100101102103104 ... 611

Week's Top Stories